Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Sales and Divestitures: 2016-2024

Historic Gains from Sales and Divestitures for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $2.3 million.

  • Tg Therapeutics' Gains from Sales and Divestitures fell 3.36% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 3.36%. This contributed to the annual value of $2.3 million for FY2024, which is 9.91% down from last year.
  • As of FY2024, Tg Therapeutics' Gains from Sales and Divestitures stood at $2.3 million, which was down 9.91% from $2.5 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Gains from Sales and Divestitures peaked at $6.3 million during FY2022, and registered a low of $1.1 million during FY2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $2.5 million (2023), whereas its average is $3.7 million.
  • As far as peak fluctuations go, Tg Therapeutics' Gains from Sales and Divestitures soared by 382.98% in 2022, and later plummeted by 60.26% in 2023.
  • Tg Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $1.1 million in 2020, then increased by 19.75% to $1.3 million in 2021, then skyrocketed by 382.98% to $6.3 million in 2022, then slumped by 60.26% to $2.5 million in 2023, then fell by 9.91% to $2.3 million in 2024.